NYSE:BXLT (BXLT) (BXLT) Stock Price, News & Analysis → Radical change coming — do this NOW to protect yourself (From Weiss Ratings) (Ad) Free BXLT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$46.02▼$46.0250-Day Range N/A52-Week Range$29.83▼$46.52VolumeN/AAverage Volume12.66 million shsMarket CapitalizationN/AP/E Ratio15.49Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (BXLT) alerts: Email Address Ad Weiss RatingsRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and radically change life in America as we know it today. And a Draconian set of technologies that could impose a new kind of financial surveillance in America. Click here to learn more. About (BXLT) Stock (NYSE:BXLT)Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.Read More Ad Weiss RatingsRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and radically change life in America as we know it today. And a Draconian set of technologies that could impose a new kind of financial surveillance in America. Click here to learn more. BXLT Stock News HeadlinesApril 5, 2024 | morningstar.comAnyMind Group Inc 5027February 25, 2024 | morningstar.comIDICO Corp JSC Ordinary Shares IDCFebruary 20, 2024 | morningstar.comHana Financial Group Inc 086790September 15, 2023 | thestreet.comBaxter Int'l. (BAX) Stock Price Target Lowered by AnalystsAugust 25, 2023 | thestreet.comAllergan Could Buy These Drug Companies Now That the Pfizer Merger Is ScuttledJuly 25, 2023 | thestreet.com4 Smart Stocks to Add to Your Portfolio in 2016, from Recon’s Kevin KellyMay 31, 2023 | msn.comFed Beige Book: Pace of hiring and pricing is slowingMay 31, 2023 | msn.comAdidas' remaining Yeezy sneakers go on saleMarch 29, 2023 | msn.comSuburban businesses accuse convicted credit card fraudster John Hancock of more crimesFebruary 17, 2023 | msn.comChevron to send over 100,000 bpd of Venezuelan oil to U.S. this monthDecember 23, 2022 | msn.comNew Vernon, B.C. supportive housing building set to openDecember 23, 2022 | msn.com1 victim identified in double shooting in College Hill, police sayNovember 16, 2022 | msn.comCrews continue working to restore water service in ZavallaOctober 4, 2022 | msn.comMorgan City man arrested for stealing car, multiple active warrants foundSeptember 8, 2022 | msn.comEvo Morales accuses Bolivian ministers of executing «a black plan» against himAugust 23, 2022 | thestreet.comPayPal Is Cramer and Mohr’s Newest Addition to the AAP PortfolioAugust 12, 2022 | msn.comVideo Explains How the Earth Is Spinning Faster Lately And Viewers Have CommentsMarch 1, 2022 | thestreet.com4 Pharmaceutical Stocks to Buy in Wake of Shire-Baxalta BidSee More Headlines Receive BXLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (BXLT) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/28/2016Today6/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNYSE:BXLT CUSIPN/A CIK1620546 Webwww.baxalta.com Phone+1-224-9402000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio15.49 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report BXLT Stock Analysis - Frequently Asked Questions How were (BXLT)'s earnings last quarter? (BXLT) (NYSE:BXLT) posted its earnings results on Thursday, April, 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.01. The biotechnology company earned $1.50 billion during the quarter, compared to analyst estimates of $1.47 billion. The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.40 earnings per share. Is (BXLT) a good dividend stock? (BXLT) (NYSE:BXLT) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 9.43%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for BXLT. What other stocks do shareholders of (BXLT) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (BXLT) investors own include Baxter International (BAX), Hawkins (HWKN), AbbVie (ABBV), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Alibaba Group (BABA), Bank of America (BAC), Edwards Lifesciences (EW), Gilead Sciences (GILD) and Micron Technology (MU). This page (NYSE:BXLT) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredRevealed: The Unknown Biotech Powering AI in HealthcareThe CEO of Google predicted this is "one of the most important things for humanity." We're standing at the ...Behind the Markets | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BXLT) Please log in to your account or sign up in order to add this asset to your watchlist. Share (BXLT) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.